J

Johnson & Johnson

Makes prescription drugs and medical devices

Field Product Specialist

Full-TimeUpdated on 10/23/2026Deadline 10/26/26
€48.6k - €77.4k+ Annual bonus + Sales commissions
Mid, Senior
Bachelor's
Pomezia, Italy
In Person
Customer Experience & SupportCustomer Success

About the job

Requirements
  • A degree in engineering or life science.
  • Three to five years of experience in a clinical role in the electrophysiology field.
  • Technical and clinical skills in electrophysiology, including basic clinical understanding and deep product knowledge to support electrophysiology cases, understand new product needs, and convey information to field organizations and customers.
  • Analytical thinking, including systematically gathering, organizing, and synthesizing relevant information.
  • Project management experience managing expectations of internal and external partners, gathering deliverable requirements, and supporting business requests.
  • Ability to anticipate and address internal or external customer needs through timely program or project implementation.
  • Ability to explain, describe, and convey information in formal and informal presentation settings.
  • Ability to work effectively with others toward shared goals and manage a team of product managers.
  • Significant leadership skills.
  • Experience as a trainer.
  • Project management skills.
  • Effective verbal and written communication skills.
Responsibilities
  • Drive successful adoption and maximized usage of NP since launch.
  • Build relationships with NP users and key opinion leaders across EMEA to connect NP usage with current clinical strategies, particularly for atrial fibrillation treatment.
  • Work with the Clinical department to ensure NP has a strong clinical and scientific impact based on key opinion leader usage of the system and catheters.
  • Enhance the effective penetration and adoption of new technologies.
  • Work with EMEA, NPM, and global marketing teams and R&D to support the introduction of new technologies.
  • Support the Worldwide Clinical Marketing team in identifying critical-to-success clinical claims and validating those claims.
  • Implement marketing strategy in the field, focusing on critical-to-success product applications.
  • Ensure local clinical teams understand and deploy marketing strategies to support clinical application of BW products and rapid therapy adoption.
  • Work with local Clinical Managers and Clinical Specialists to maximize utilization of CARTO 3 systems and new technologies, particularly in atrial fibrillation.
  • Build strong relationships with EMEA key opinion leaders and meet with CSS working with them to define support and clinical advice for their laboratories.
  • Ensure strong EMEA communication about current atrial fibrillation treatment options using the company's technologies.
  • Maximize key opinion leader adoption of CARTO 3 and new technologies in atrial fibrillation treatment.
  • Share clinical best practices and identify critical success factors.
  • Represent the Clinical HUB within EMEA with other CDM colleagues and ensure productive communication.
  • Maximize assigned territory utilization per system.
  • Communicate business issues or opportunities to the next management level.
  • Ensure subordinates follow company Health, Safety and Environmental guidelines and have the resources needed to comply.
  • Ensure personal and company compliance with applicable federal, state, local, and company regulations, policies, and procedures.
  • Perform other duties as assigned.
Desired Qualifications
  • Cross-functional collaboration.
  • Customer acquisition.
  • Customer centricity.
  • Customer journey mapping.
  • Customer relationship management (CRM).
  • Customer retention.
  • Customer success management (CSM).
  • Data gathering and analysis.
  • Leveraging information.
  • Organizing.
  • Proactive behavior.
  • Problem solving.
  • Process improvement.
  • Relationship building.
  • Sales enablement.
  • Sales support.
  • Service excellence.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.